

SPEAKERS' BIOGRAPHIES



Chairman

Prof. Bruce Sands, M.D., M.S.

Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York City, NY, USA

Bruce Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands was awarded his BA and MD from Boston University and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr. Sands is widely recognized for his clinical investigations of new therapeutics for the inflammatory bowel diseases and has published more than 250 original manuscripts. He was the lead investigator of the landmark studies ACCENT 2, UNIFI and VARSITY, published in the New England Journal of Medicine.



Prof. William Sandborn, M.D.

University of California San Diego School of Medicine and Co-Founder and Chief Medical Officer at Shoreline Biosciences, CA, USA

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. From 2011-2021 he was Professor of Medicine and Chief of the Division of Gastroenterology at the University of California San Diego (UCSD). Since 2021 he has continued as a Professor of Medicine at UCSD and served as the Chief Medical Officer at Shoreline Biosciences. Dr. Sandborn has published over 856 peer reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. His h-index is 140. In 2019 he was awarded the Sherman Prize for his work in inflammatory bowel disease. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease, and NK and macrophage cell therapy for oncologic and autoimmune diseases. Dr. Sandborn was a co-founder of Santarus (founded 1998, IPO in 2004, acquired by Salix Pharmaceuticals in 2013), a member of the board of directors for Prometheus Biosciences (from 2017 until IPO in 2021), and a co-founder of Shoreline Biosciences (founded 2020).



Didier Scherrer, Ph.D.

Vice President of R&D

Prior to joining Abivax, Dr. Didier Scherrer combined the functions of CEO and Scientific Director at Splicos. Dr. Scherrer has a Ph.D. in Molecular Pharmacology. He completed his post-doctoral studies at Harvard Medical School and then at the Stanford University School of Medicine. Following his role as a Research Director at Entelos (California - USA) from 2000 to 2005, he joined the Research Department of Astra-Zeneca as Associate Director (Capability Pathways - Discovery Enabling Capabilities and Sciences). In 2008, Dr. Scherrer joined LFB Biotechnologies as Head of Research where he led a team of fifty scientists in charge of developing the portfolio of therapeutic proteins in oncology, autoimmune diseases and hematology-oncology. Dr. Scherrer is the author of numerous publications and presentations in the field of systems biology applied to the research and drug development.